Given their critical role in maintaining chromosome stability, kinetochores present a promising [therapeutic target]. Drugs that specifically disrupt kinetochore function can induce cell death in cancer cells by exacerbating chromosomal instability. For example, inhibitors targeting the Ndc80 complex have shown potential in preclinical studies. However, the challenge lies in selectively targeting cancer cells without affecting normal dividing cells, which also rely on functional kinetochores.
